Published in Hepatitis Weekly, June 20th, 2005
The results demonstrate that Albuferon (albumin-interferon alpha) exhibits more antiviral activity at clinically achieved serum levels than standard interferon alpha or the modified interferons, Pegasys (peginterferon alfa-2a) and Peg-Intron (peginterferon alfa-2b).
The data were presented in Chicago at Digestive Disease Week 2005 in a poster presentation entitled, "Albuferon Exhibits Efficient Anti-HCV Activity in Cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.